Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Island Doctors to host community diabetes awareness campaigns across NE Florida

On October 12th and 13th, Island Doctors will participate, sponsor, and co-host three events in Putnam and St. Johns County, Florida. The events are part of Island Doctors continued commitment to community diabetes awareness campaigns across NE Florida.

12 Oct 2013

Astrazeneca, Janssen To Promote Novel Prostate Cancer Treatment In Japan

...

11 Oct 2013

Scientists to combine NK cell therapy with immunocytokine to target childhood cancer

Researchers have made rapid advances in understanding how to manipulate the immune system safely to destroy cancer cells. Adoptive transfer of haploidentical natural killer cells has shown promise as a treatment option to target and kill cancer cells in a less toxic way than conventional therapies. Now for the first time, scientists will combine NK cell therapy with an immunocytokine to target children with relapsed/refractory disease including those with bulky tumors.

11 Oct 2013

Reducing risk factors like hypertension might lower risk of heart disease for childhood survivors

For childhood cancer survivors, risk factors associated with lifestyle, particularly hypertension, dramatically increase the likelihood of developing serious heart problems as adults, according to a national study led by St. Jude Children's Research Hospital. The findings appear in the current issue of the Journal of Clinical Oncology.

11 Oct 2013

Cleveland healthcare institutions receive $1M grant to develop Stroke Clinical Trials Coordinating Center

...

11 Oct 2013

Research delves deeply into genomics of glioblastoma multiforme cases to better target disease

When The Cancer Genome Atlas launched its massively collaborative approach to organ-by-organ genomic analysis of cancers, the brain had both the benefit, and the challenge, of going first.

11 Oct 2013

Bluhm Institute enrolls first patient in SALUS trial to evaluate movable, non-metallic heart valve

Northwestern's Bluhm Cardiovascular Institute has enrolled its first participant in SALUS, a clinical trial studying the effectiveness of a prosthetic aortic heart valve that can be placed without open-heart surgery.

10 Oct 2013

Researcher receives grant to explore HER2-positive breast tumor susceptibility to PARP inhibitors

Shih-Hsin (Eddy) Yang, M.D., Ph.D., the ROAR Southeast Cancer Foundation Endowed Chair in the University of Alabama at Birmingham Department of Radiation Oncology, has received a $450,000 grant from Susan G. Komen for the Cure to further investigate HER2-positive breast tumor susceptibility to PARP inhibitors.

10 Oct 2013

Compugen drug candidate prevents autoimmune type I diabetes in animal model

Compugen Ltd., announced today that CGEN-15001, an Fc fusion protein drug candidate derived from a novel immune checkpoint protein discovered by Compugen, has been shown to be highly efficient in preventing the development of disease in a well-accepted animal model of autoimmune type I diabetes, known also as juvenile diabetes.

9 Oct 2013

HMI, NCONN to collaborate on various educational initiatives for oncology health professionals

Haymarket Media Inc. and the National Coalition of Oncology Nurse Navigators have formed a partnership to collaborate on a wide variety of educational initiatives for the oncology health professionals they serve.

9 Oct 2013

ARIAD announces changes in Iclusig product labeling to reflect updated safety information

ARIAD Pharmaceuticals, Inc. today announced results of its review of updated clinical data from the pivotal PACE trial of Iclusig® (ponatinib) and actions that it is taking following consultations with the U.S. Food and Drug Administration (FDA).

9 Oct 2013

$Study examines use of single-fraction radiation treatment for prostate cancer, bone metastases$

Study examines use of single-fraction radiation treatment for prostate cancer, bone metastases

Justin E. Bekelman, M.D., of the University of Pennsylvania Perelman School of Medicine, Philadelphia, and colleagues conducted a study to examine whether single-fraction radiation treatment, shown to be as effective as multiple-fraction treatment with less potential for harm, has been incorporated into routine clinical practice for Medicare beneficiaries with prostate cancer and at what cost savings.

9 Oct 2013

DSP to set up anti-cancer drugs sales company in US

Dainippon Sumitomo Pharma Co., Ltd. (DSP) announced on October 9 that it has decided to establish an anti-cancer drugs sales company in the United States as a wholly-owned subsidiary of DSP's 100% owned U.S. holding company.

9 Oct 2013

CNIO researcher identifies new molecular mechanism that regulates genome stability, cell proliferation

Cell division is an essential process for the development of an organism. This process, however, can cause tumour growth when it stops working properly. Tumour cells accumulate alterations in their genetic material, and this makes them divide in an uncontrolled fashion, thus encouraging growth of the tumour.

9 Oct 2013

Janssen buys all rights from GSK to develop, commercialize hepatitis C compound

Janssen Pharmaceuticals, Inc. announced today the acquisition of the investigational compound GSK2336805, an NS5a replication complex inhibitor in Phase 2 development for the treatment of chronic hepatitis C, from an affiliate of GlaxoSmithKline plc.

9 Oct 2013

Bayer HealthCare receives FDA approval for Adempas tablets

Bayer HealthCare announced today that the United States Food and Drug Administration has approved Adempas (riociguat) tablets for: (i) the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (WHO Group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class; and (ii) the treatment of adults with pulmonary arterial hypertension (WHO Group 1) to improve exercise capacity, improve WHO functional class and delay clinical worsening.

9 Oct 2013

Arrowhead initiates Phase 1 study of ARC-520 for treatment against chronic HBV infection

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it completed enrollment in a Phase 1 clinical trial of ARC-520, its RNAi-based candidate against chronic hepatitis B virus infection.

9 Oct 2013

MRFBC launches clinical trial to assess impact of bevacizumab and vemurafenib in melanoma patients

The Melanoma Research Foundation Breakthrough Consortium has launched a new clinical trial to assess the impact of concomitant administration of bevacizumab (Avastin) with vemurafenib (Zelboraf) in patients with BRAFV600 mutation positive metastatic melanoma.

8 Oct 2013

Forma Achieves First Milestone In Celgene Collaboration

...

8 Oct 2013

Clinical study to determine sentinel lymph node surgery in patients with breast cancer

Judy C. Boughey, M.D., Kelly K. Hunt, M.D., and colleagues for the Alliance for Clinical Trials in Oncology conducted a study to determine the false-negative rate of sentinel lymph node surgery in patients with node-positive breast cancer receiving chemotherapy before surgery.

8 Oct 2013

Oncology News and Research

Further Reading

Island Doctors to host community diabetes awareness campaigns across NE Florida

Astrazeneca, Janssen To Promote Novel Prostate Cancer Treatment In Japan

Scientists to combine NK cell therapy with immunocytokine to target childhood cancer

Reducing risk factors like hypertension might lower risk of heart disease for childhood survivors

Cleveland healthcare institutions receive $1M grant to develop Stroke Clinical Trials Coordinating Center

Research delves deeply into genomics of glioblastoma multiforme cases to better target disease

Bluhm Institute enrolls first patient in SALUS trial to evaluate movable, non-metallic heart valve

Researcher receives grant to explore HER2-positive breast tumor susceptibility to PARP inhibitors

Compugen drug candidate prevents autoimmune type I diabetes in animal model

HMI, NCONN to collaborate on various educational initiatives for oncology health professionals

ARIAD announces changes in Iclusig product labeling to reflect updated safety information

Study examines use of single-fraction radiation treatment for prostate cancer, bone metastases

DSP to set up anti-cancer drugs sales company in US

CNIO researcher identifies new molecular mechanism that regulates genome stability, cell proliferation

Janssen buys all rights from GSK to develop, commercialize hepatitis C compound

Bayer HealthCare receives FDA approval for Adempas tablets

Arrowhead initiates Phase 1 study of ARC-520 for treatment against chronic HBV infection

MRFBC launches clinical trial to assess impact of bevacizumab and vemurafenib in melanoma patients

Forma Achieves First Milestone In Celgene Collaboration

Clinical study to determine sentinel lymph node surgery in patients with breast cancer

Event guide: The 9th DDR Inhibitors Summit 2026 eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News